Veterinary Medicines

PENETHAONE Powder and solvent for suspension for injection for cattle

Authorised
  • Penethamate hydriodide
Download as PDF

Product identification

Medicine name:
PENETHAONE Powder and solvent for suspension for injection for cattle
Penethaone 236.3 mg/ml Poeder en oplosmiddel voor suspensie voor injectie
Penethaone 236.3 mg/ml Poudre et solvant pour suspension injectable
Penethaone 236.3 mg/ml Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension
Active substance:
  • Penethamate hydriodide
Target species:
  • Cattle (lactating cow)
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Penethamate hydriodide
    236.30
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Powder and solvent for suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Cattle (lactating cow)
      • Meat and offal
        4
        day
      • Milk
        no withdrawal period
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01CE90
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Belgium
Package description:
  • box containing 10 x 10,000,000 IU powder vial and 10 x 36 ml solvent vial
  • box containing 5 x 10,000,000 IU powder vial and 5 x 36 ml solvent vial
  • box containing 1 x 10,000,000 IU powder vial and 1 x 36 ml solvent vial
  • box containing 10 x 5,000,000 IU powder vial and 10 x 18 ml solvent vial
  • box containing 5 x 5,000,000 IU powder vial and 5 x 18 ml solvent vial
  • box containing 1 x 5,000,000 IU powder vial and 1 x 18 ml solvent vial

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Divasa Farmavic S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Divasa Farmavic S.A.
Responsible authority:
  • Federal Agency For Medicines And Health Products
Authorisation number:
This information is not available for this product.
Date of authorisation status change:
Reference member state:
  • Spain
Procedure number:
  • ES/V/0226/001
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Czechia
  • Denmark
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Lithuania
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

English (PDF)
Published on: 26/12/2023
Download
Dutch (PDF)
Published on: 22/03/2022
Download
French (PDF)
Published on: 22/03/2022
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 22/03/2022
Download
French (PDF)
Published on: 22/03/2022
Download
German (PDF)
Published on: 22/03/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."